R. Marshall Austin, MD, PhD
Professor of Pathology

Dr. Austin is a member of the Division of Gynecologic Pathology.

Office Location:
Pathology Department
Room 4427
Magee-Womens Hospital
300 Halket Street
Pittsburgh, PA 15213

Contact Information:
Office Telephone: 412-641-3347
Office Fax: 412-641-1675
Pager: 412-917-9769
Email Address: raustin@magee.edu

Dr. Austin has been Professor of Pathology and Director of Cytopathology at Magee-Womens Hospital of University of Pittsburgh Medical Center since 2005. Dr. Austin is a 1977 graduate of the Duke University School of Medicine Medical Scientist Training Program (MD, PhD) with his PhD dissertation in virology. He received additional Pathology training at Duke and postgraduate subspecialty training in Gynecologic and Breast Pathology and Cytopathology from 1983-1986 at the Armed Forces Institute of Pathology.

Dr. Austinís current areas of research interest focus on cervical cancer screening, cervical neoplasia risk stratification modeling and risk management, new cervical screening technologies, and public and professional education. He is a past President of the American Society of Cytopathology (2004-2005).

Education

  • PhD - Duke University, 1976
  • MD - Duke University, 1977

Research Interests

  • Risk Management in Cervical Cancer Screening
  • Gynecological Cytopathology
  • New Technology Enhancements for Cervical Cancer Screening

Certifications

AP/CP, Cytopathology, Medical Microbiology

Specialties

Gynecologic and Breast Surgical Pathology (AFIP 1983-1986)

Awards and Honors

  • Best Doctors Award - Pittsburgh Magazine, 2012, 2013
  • Best Doctors in America Award, 2005-2013
  • College of American Pathologists - William E. Kuehn Outstanding Communicator Award, 2001
  • College of American Pathologists - Presidentís Award, 1997

Selected Publications

View Dr. Austin's publications on PubMed

Austin RM, Zhao C. Type 1 and Type 2 Cervical Carcinomas: Some Cervical Carcinomas Are More Difficult to Prevent with Screening. Cytopathology 2012; 23: 6-12.

Zhao C, Chen X, Onisko A, Kanbour A, Austin RM. Follow-up outcomes for a large cohort of U.S. women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. Gynecologic Oncology 2011; 122: 291-296.

Gao FF, Austin RM, Zhao C. Histopathologic Follow-up and Human Papillomavirus DNA Test Results in 290 Patients with High Grade Squamous Intraepithelial Lesion Papanicolaou Test Results. Cancer Cytopathol. 2011; 119: 377-386.

Austin RM, Zhao C. Unrecognized Risks Associated with New Cervical Screening Guidelines for Younger Women. Archives of Pathology and Laboratory Medicine 2011; 135: 1080.

Austin RM, Zhao C. Observations on Pap Test Litigation. Pathology Case Reviews 2011; 16: 73-82.

Davey DD, Greenspan D, Kurtycz DFI, Husain M, Austin RM. Atypical Squamous Cells, Cannot exclude High-Grade Squamous Intraepithelial Lesion: Review of Ancillary Testing Modalities and Implications for Follow-up. J Lower Gen Tr Dis 2010; 14: 206-214.

Austin RM. Exhortations to Abandon the Pap Test as a Routine Initial Cervical Screening Test Are Still Premature and Carry Significant Risks. Diagnostic Cytopathology 2010; 38: 783-787.

Zhao C, Zhao S, Heider A, Austin RM. Significance of High Risk HPV DNA Detection in Women 50 and Older with Squamous Cell Pap Test Abnormalities. Archives of Pathology and Laboratory Medicine 2010; 134:1130-1135.

Zhao C, Florea A, Austin RM. Clinical Utility of Adjunctive High Risk HPV DNA Testing in Women with Pap Test findings of Atypical Glandular Cells. Archives of Pathology and Laboratory Medicine 2010; 134: 103 - 108.

Austin RM. Computer-Assisted Papanicolaou Imaging: Another Valuable Tool in the Challenge of Papanicolaou Test Screening for Glandular Neoplasia. Cancer Cytopathology 2010; 118: 65-67.

Austin RM, Onisko A, Druzdel M. The Pittsburgh Cervical Cancer Screening Model: A Risk Assessment Tool. Archives of Pathology and Laboratory Medicine November 2010; 134: 744-750.

Zhao CZ, Austin RM. High Risk HPV DNA Testing Is Useful For Disease Risk Stratification In Women With Unsatisfactory Liquid-Based Cytology (LBC) Pap Test Results. Journal of the Lower Genital Tract 2009; 13: 79-84.

Zhao C, Florea A, Onisko A, Austin RM. Histologic Follow-up Results in 662 Patients with Pap Test Findings of Atypical Glandular Cells: Results From a Large Academic Womens Hospital Laboratory Employing Sensitive Screening Methods. Gynecologic Oncology 2009; 114: 383-389.

Austin RM, Zhao C. Test Group Biases and Ethical Issues Mar New England Journal of Medicine Study Promoting HPV Screening in Rural India. CytoJournal 2009; 6: 12.

Zhao CZ, Austin RM. Adjunctive High Risk HPV DNA Testing is a Useful Option for Disease Risk Assessment in Negative Pap Tests Without an Endocervical/Transformation Zone Sample. 2008; 114: 242-248, 2008.

Bandyopadhyay S, Austin RM, Dabbs D, Zhao CZ. Adjunctive HPV DNA Testing is a Useful Option in Some Clinical Settings for Disease Risk Assessment and Triage of Women with ASC-H Pap Results. Arch Pathol Lab Med 2008; 132: 1874-1881.

Cibas ES, Gamerman GE, Alonzo TA, Austin RM, Bolick DR, Glant MD, Henry MR, Moriarty AT, Molina TJ, Rushing L. Slowman SS, Torno R, Eisenhut CC. The MonoPrep Pap Test for the Detection Cervical Cancer and Its Precursors: Results of a Multi-Center Clinical Trial. American Journal of Clinical Pathology 2008; 129: 193-201.

Austin RM. Dismantling of the U.S. Cytotechnology Educational Infrastructure is Premature and Carries Significant Risks. Archives of Pathology and Laboratory Medicine; 2008; 132: 154-158.

Davey DD, Cox, JT, Austin, RM, Birdsong, G, Colgan, TJ, Howell, LP, Husain, MH, Darragh, TM. Cervical Cytology Specimen Adequacy: Patient Management Guidelines and Optimizing Specimen Collection. Journal of Lower Genital Tract Disease 2008; 12: 71-81.